Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine - HIVNET 012

被引:38
作者
Eshleman, SH
Guay, LA
Wang, J
Mwatha, A
Brown, ER
Musoke, P
Mmiro, F
Jackson, JB
机构
[1] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Makerere Univ, Kampala, Uganda
关键词
HIV-1; resistance; subtype; nevirapine; mother-to-child transmission; Uganda;
D O I
10.1097/01.qai.0000174656.71276.d6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The HIVNET 012 trial in Uganda demonstrated that single-dose nevirapine (NVP) can prevent HIV-1 mother-to-child transmission. NVP resistance (NVPR) mutations were detected in 25% of women 6 to 8 weeks after NVP, with a higher rate of NVPR in women with subtype D than A. This study examined emergence and fading of specific NVPR mutations in women with these subtypes. Methods: Plasma HIV-1 was analyzed with the ViroSeq genotyping system (Celera Diagnostics, Alameda, CA). Genotypes were obtained from paired samples collected 7 days and 6 to 8 weeks after NVP from 140 women, 83 with subtype A and 57 with subtype D. Results: The rate of NVPR was similar in women with subtype Avs. D at 7 days but was higher in subtype D than A at 6 to 8 weeks. The higher rate of NVPR in subtype D was explained by at least 2 factors: Y181C faded from detection at a greater rate in women with subtype A (odds ratio = 3.06; 95% CI, 1.04, 8.90) and K103N accumulated at a greater rate in women with subtype D (odds ratio = 1.74; 95% CI, 0.62, 4.87). Conclusions: HIV-1 subtype influences selection and fading of HIV-1 variants with specific drug resistance mutations after antiretroviral drug exposure.
引用
收藏
页码:24 / 29
页数:6
相关论文
共 41 条
[1]  
Abecasis A, 2003, ANTIVIR THER, V8, pU121
[2]   Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility [J].
Apetrei, C ;
Descamps, D ;
Collin, G ;
Loussert-Ajaka, I ;
Damond, F ;
Duca, M ;
Simon, F ;
Brun-Vézinet, F .
JOURNAL OF VIROLOGY, 1998, 72 (05) :3534-3538
[3]   Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults [J].
Becker-Pergola, G ;
Kataaha, P ;
Johnston-Dow, L ;
Fung, S ;
Jackson, JB ;
Eshleman, SH .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (08) :807-813
[4]   Comparison of image compression viability for lossy and lossless JPEG and Wavelet data reduction in coronary angiography [J].
Brennecke, R ;
Bürgel, U ;
Rippin, G ;
Post, F ;
Rupprecht, HE ;
Meyer, J .
INTERNATIONAL JOURNAL OF CARDIAC IMAGING, 2001, 17 (01) :1-12
[5]   Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants [J].
Collins, JA ;
Thompson, MG ;
Paintsil, E ;
Ricketts, M ;
Gedzior, J ;
Alexander, L .
JOURNAL OF VIROLOGY, 2004, 78 (02) :603-611
[6]  
Descamps D, 1998, AIDS, V12, P1109
[7]   Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission - A randomized trial [J].
Dorenbaum, A ;
Cunningham, CK ;
Gelber, RD ;
Culnane, M ;
Mofenson, L ;
Britto, P ;
Rekacewicz, C ;
Newell, ML ;
Delfraissy, JF ;
Cunningham-Schrader, B ;
Mirochnick, M ;
Sullivan, JL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (02) :189-198
[8]   Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus type 1 subtypes may influence mutational routes to drug resistance [J].
Dumans, AT ;
Soares, MA ;
Machado, ES ;
Hué, S ;
Brindeiro, RM ;
Pillay, D ;
Tanuri, A .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (07) :1232-1238
[9]   Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP [J].
Eshleman, SH ;
Hoover, DR ;
Chen, S ;
Hudelson, SE ;
Guay, LA ;
Mwatha, A ;
Fiscus, SA ;
Mmiro, F ;
Musoke, P ;
Jackson, JB ;
Kumwenda, N ;
Taha, T .
JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (01) :30-36
[10]   Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose NVP prophylaxis: HIVNET 012 [J].
Eshleman, SH ;
Guay, LA ;
Mwatha, A ;
Cunningham, SP ;
Brown, ER ;
Musoke, P ;
Mmiro, F ;
Jackson, JB .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2004, 20 (06) :595-599